• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于预测胃癌预后的3-miRNA标志物的开发与临床验证

Development and clinical validation of a 3-miRNA signature to predict prognosis of gastric cancer.

作者信息

Qi Wenqian, Zhang Qian

机构信息

Department of Gastroenterology, China-Japan Union Hospital, Jilin University, Changchun, Jilin Province, China.

出版信息

PeerJ. 2021 Feb 3;9:e10462. doi: 10.7717/peerj.10462. eCollection 2021.

DOI:10.7717/peerj.10462
PMID:33604158
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7866890/
Abstract

AIMS

Identification of miRNA signature to predict the prognosis of gastric cancer (GC) patients by integrating bioinformatics and experimental validation.

METHODS

The miRNA expression profile and clinical data of GC were collected. The univariable and LASSO-Cox regression were used to construct the risk signature. The receiver operating characteristic (ROC) curve analysis confirmed the good performance of the prognostic model.

RESULTS

A 3-miRNA prognostic signature was constructed, which included hsa-miR-126-3p, hsa-miR-143-5p, and hsa-miR-1275. A nomogram, including the prognostic signature to predict the overall survival, was established, and internal validation in the The Cancer Genome Atlas (TCGA) cohort was performed. We found that compared with the traditional pathological stage, the nomogram was the best at predicting the prognosis.

CONCLUSIONS

The predictive model and the nomogram will enable patients with GC to be more accurately managed in clinical practice.

摘要

目的

通过整合生物信息学和实验验证,鉴定用于预测胃癌(GC)患者预后的miRNA特征。

方法

收集GC的miRNA表达谱和临床数据。采用单变量和LASSO-Cox回归构建风险特征。受试者工作特征(ROC)曲线分析证实了预后模型的良好性能。

结果

构建了一个包含hsa-miR-126-3p、hsa-miR-143-5p和hsa-miR-1275的3-miRNA预后特征。建立了一个包括预后特征以预测总生存期的列线图,并在癌症基因组图谱(TCGA)队列中进行了内部验证。我们发现,与传统病理分期相比,列线图在预测预后方面表现最佳。

结论

该预测模型和列线图将使GC患者在临床实践中得到更准确的管理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a9b/7866890/7521971e5079/peerj-09-10462-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a9b/7866890/0b05fe34d82e/peerj-09-10462-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a9b/7866890/7be11857b656/peerj-09-10462-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a9b/7866890/0718a75c553a/peerj-09-10462-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a9b/7866890/926185265b3e/peerj-09-10462-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a9b/7866890/2f76193da6e1/peerj-09-10462-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a9b/7866890/9896d6a4e840/peerj-09-10462-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a9b/7866890/7bdb5c9d9174/peerj-09-10462-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a9b/7866890/7521971e5079/peerj-09-10462-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a9b/7866890/0b05fe34d82e/peerj-09-10462-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a9b/7866890/7be11857b656/peerj-09-10462-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a9b/7866890/0718a75c553a/peerj-09-10462-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a9b/7866890/926185265b3e/peerj-09-10462-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a9b/7866890/2f76193da6e1/peerj-09-10462-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a9b/7866890/9896d6a4e840/peerj-09-10462-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a9b/7866890/7bdb5c9d9174/peerj-09-10462-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a9b/7866890/7521971e5079/peerj-09-10462-g008.jpg

相似文献

1
Development and clinical validation of a 3-miRNA signature to predict prognosis of gastric cancer.用于预测胃癌预后的3-miRNA标志物的开发与临床验证
PeerJ. 2021 Feb 3;9:e10462. doi: 10.7717/peerj.10462. eCollection 2021.
2
A Panel of MicroRNA Signature as a Tool for Predicting Survival of Patients with Urothelial Carcinoma of the Bladder.微 RNA 特征面板作为预测膀胱尿路上皮癌患者生存的工具。
Dis Markers. 2018 Jun 20;2018:5468672. doi: 10.1155/2018/5468672. eCollection 2018.
3
A Five-microRNA Signature as Prognostic Biomarker in Colorectal Cancer by Bioinformatics Analysis.通过生物信息学分析确定一种五微RNA特征作为结直肠癌的预后生物标志物
Front Oncol. 2019 Nov 12;9:1207. doi: 10.3389/fonc.2019.01207. eCollection 2019.
4
A risk score system based on a six-microRNA signature predicts the overall survival of patients with ovarian cancer.基于六个 microRNA 特征的风险评分系统可预测卵巢癌患者的总生存期。
J Ovarian Res. 2022 May 6;15(1):54. doi: 10.1186/s13048-022-00980-8.
5
A six-microRNA signature can better predict overall survival of patients with esophagus adenocarcinoma.一种由六种微小RNA组成的特征能够更好地预测食管腺癌患者的总生存期。
PeerJ. 2019 Jul 25;7:e7353. doi: 10.7717/peerj.7353. eCollection 2019.
6
Prognostic signature composed of transcription factors accurately predicts the prognosis of gastric cancer patients.由转录因子组成的预后特征能够准确预测胃癌患者的预后。
Cancer Cell Int. 2021 Jul 7;21(1):357. doi: 10.1186/s12935-021-02008-5.
7
Development and Validation of a Prognostic Nomogram for Gastric Cancer Based on DNA Methylation-Driven Differentially Expressed Genes.基于 DNA 甲基化驱动的差异表达基因构建胃癌预后列线图模型的建立与验证。
Int J Biol Sci. 2020 Feb 10;16(7):1153-1165. doi: 10.7150/ijbs.41587. eCollection 2020.
8
Genome-wide identification of a novel miRNA-based signature to predict recurrence in patients with gastric cancer.基于全基因组鉴定的新型 miRNA 标志物预测胃癌患者的复发。
Mol Oncol. 2018 Dec;12(12):2072-2084. doi: 10.1002/1878-0261.12385. Epub 2018 Oct 10.
9
Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.基于统计分析构建新型膀胱癌 mRNA 特征预测预后模型。
BMC Cancer. 2021 Jul 27;21(1):858. doi: 10.1186/s12885-021-08611-z.
10
Genome-wide analysis to identify a novel microRNA signature that predicts survival in patients with stomach adenocarcinoma.全基因组分析以鉴定一种预测胃腺癌患者生存情况的新型微小RNA特征。
J Cancer. 2019 Oct 17;10(25):6298-6313. doi: 10.7150/jca.33250. eCollection 2019.

引用本文的文献

1
MiR-1275 Targeting SPARC Promotes Gambogic Acid-Induced Inhibition of Gastric Cancer.靶向SPARC的MiR-1275促进藤黄酸诱导的胃癌抑制作用。
Biochem Genet. 2023 Dec;61(6):2481-2495. doi: 10.1007/s10528-023-10381-1. Epub 2023 Apr 28.
2
A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer.基于检查淋巴结数量相关特征的列线图模型预测胃癌的预后并指导临床治疗。
Front Immunol. 2022 Nov 2;13:947802. doi: 10.3389/fimmu.2022.947802. eCollection 2022.
3
Overview of MicroRNAs as Diagnostic and Prognostic Biomarkers for High-Incidence Cancers in 2021.

本文引用的文献

1
Integrative analysis of miRNA and mRNA expression profiles reveals a novel mRNA/miRNA signature to improve risk classification for patients with gastric cancer.miRNA和mRNA表达谱的综合分析揭示了一种新的mRNA/miRNA特征,可改善胃癌患者的风险分类。
Oncol Lett. 2019 Sep;18(3):2330-2339. doi: 10.3892/ol.2019.10536. Epub 2019 Jun 27.
2
MicroRNA-1275 inhibits cell migration and invasion in gastric cancer by regulating vimentin and E-cadherin via JAZF1.MicroRNA-1275 通过调控 JAZF1 抑制胃癌细胞迁移和侵袭并影响波形蛋白和 E-钙黏蛋白的表达
BMC Cancer. 2019 Jul 29;19(1):740. doi: 10.1186/s12885-019-5929-1.
3
Analysis of microRNA expression profiles reveals a 5‑microRNA prognostic signature for predicting overall survival time in patients with gastric adenocarcinoma.
2021 年高发性癌症的 microRNAs 作为诊断和预后生物标志物概述。
Int J Mol Sci. 2022 Sep 27;23(19):11389. doi: 10.3390/ijms231911389.
4
Identification of a chromatin regulator signature and potential candidate drugs for bladder cancer.鉴定膀胱癌的染色质调控因子特征和潜在候选药物。
Hereditas. 2022 Feb 7;159(1):13. doi: 10.1186/s41065-021-00212-x.
5
Identification of a novel signature based on unfolded protein response-related gene for predicting prognosis in bladder cancer.基于未折叠蛋白反应相关基因的新型标志物鉴定用于预测膀胱癌的预后。
Hum Genomics. 2021 Dec 20;15(1):73. doi: 10.1186/s40246-021-00372-x.
分析 microRNA 表达谱揭示了 5 个 microRNA 预后标志物,可预测胃腺癌患者的总生存时间。
Oncol Rep. 2019 May;41(5):2775-2789. doi: 10.3892/or.2019.7048. Epub 2019 Mar 7.
4
A five-miRNA signature predicts survival in gastric cancer using bioinformatics analysis.基于生物信息学分析的五miRNA -signature 预测胃癌患者的生存情况。
Gene. 2019 May 30;699:125-134. doi: 10.1016/j.gene.2019.02.058. Epub 2019 Mar 5.
5
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.估算 2018 年全球癌症发病率和死亡率:GLOBOCAN 来源和方法。
Int J Cancer. 2019 Apr 15;144(8):1941-1953. doi: 10.1002/ijc.31937. Epub 2018 Dec 6.
6
Three-microRNA signature identified by bioinformatics analysis predicts prognosis of gastric cancer patients.基于生物信息学分析鉴定的三 miRNA -signature 预测胃癌患者的预后。
World J Gastroenterol. 2018 Mar 21;24(11):1206-1215. doi: 10.3748/wjg.v24.i11.1206.
7
Down-regulated serum miR-126 is associated with aggressive progression and poor prognosis of gastric cancer.血清 miR-126 下调与胃癌的侵袭性进展和不良预后相关。
Cancer Biomark. 2018;22(1):119-126. doi: 10.3233/CBM-171099.
8
miR-126 Functions as a Tumor Suppressor by Targeting SRPK1 in Human Gastric Cancer.miR-126通过靶向SRPK1在人胃癌中发挥肿瘤抑制作用。
Oncol Res. 2018 Oct 17;26(9):1345-1353. doi: 10.3727/096504018X15180508535835. Epub 2018 Feb 8.
9
GDCRNATools: an R/Bioconductor package for integrative analysis of lncRNA, miRNA and mRNA data in GDC.GDCRNATools:一个用于整合分析 GDC 中 lncRNA、miRNA 和 mRNA 数据的 R/Bioconductor 包。
Bioinformatics. 2018 Jul 15;34(14):2515-2517. doi: 10.1093/bioinformatics/bty124.
10
miR-143 and miR-145 inhibit gastric cancer cell migration and metastasis by suppressing MYO6.miR-143 和 miR-145 通过抑制 MYO6 抑制胃癌细胞迁移和转移。
Cell Death Dis. 2017 Oct 12;8(10):e3101. doi: 10.1038/cddis.2017.493.